Program

Designed for clinicians, scientists, and all other members of the cancer care and research community, the 2019 Gastrointestinal Cancers Symposium will feature a wide array of multidisciplinary topics and expert faculty will offer insights on the application of gastrointestinal advances in: cancers of the esophagus and stomach, pancreas, small bowel and hepatobiliary tract, and the colon, rectum and anus.

For trainee and early career attendees, we offer a chance to attend a Networking Luncheon, to discuss career planning and cultivating your own place in the medical community.  The meeting will also offer several other robust opportunities for networking, discussion, and face to face engagement with faculty members and other attendees.

7:00 AM-7:50 AM Complimentary Continental Breakfast
7:00 AM-6:30 PM Exhibits Open
7:50 AM-9:30 AM Welcome and General Session 1: Management of Early Stage Esophageal Cancer

Manisha Palta, MD—Chair
Duke University Medical Center

Daniela Molena, MD—Chair
Memorial Sloan Kettering Cancer Center

Nipun B. Merchant, MD
University of Miami Medical Center
Welcome of the Day

Manisha Palta, MD
Duke University Medical Center
Case Presentation

Naohisa Yahagi, MD, PhD
Keio University School of Medicine
Endoscopic Management As Definitive Therapy

Christopher Morse, MD
Massachusetts General Hospital
The Role and Need for Surgical Resection

Michael G. Haddock, MD
Mayo Clinic
Chemoradiation for Early Stage Disease

Daniela Molena, MD
Memorial Sloan Kettering Cancer Center
Current and Upcoming Clinical Trials

Panel Question and Answer
9:30 AM-10:00 AM Break
10:00 AM-11:30 AM General Session 2: Perioperative Therapies for Gastric Cancer

Paola C. Montenegro, MD—Chair
Instituto Nacional de Enfermedades Neoplasicas

Marcia Cruz-Correa, MD, PhD—Chair
The University of Puerto Rico and MD Anderson Cancer Center

Trevor Leong, MBBS, MD, FRANZCR
Peter MacCallum Cancer Centre
Neoadjuvant Strategies and Indications

David Cunningham, MD
The Royal Marsden NHS Foundation Trust, Sutton and London Hospital
Optimizing Adjuvant Therapy

Shaila Merchant, MD, MSc, MHSc, FRCSC, FACS
Queen's University
Disparities in Management of Esophago-Gastric Cancers

Marcia Cruz-Correa, MD, PhD
The University of Puerto Rico and MD Anderson Cancer Center
Current and Upcoming Clinical Trials

Panel Question and Answer
11:30 AM-1:00 PM Poster Session A: Cancers of the Esophagus and Stomach
With Complimentary Boxed Lunch 
11:30 AM-1:00 PM Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach
11:45 AM-12:45 PM Trainee and Early-Career Networking Luncheon
You can view a full list of faculty, here.
1:00 PM-1:45 PM

Rapid Abstract Session A: Cancers of the Esophagus and Stomach

Marcia Cruz-Correa, MD, PhD—Chair
The University of Puerto Rico and MD Anderson Cancer Center

Abstract 5: Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.
First Author: Hirva Mamdani, MD

Question and Answer

Abstract 6: FOLFOX versus POF (Paclitaxel plus FOLFOX) versus IP PAC (Intraperitoneal Paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial.
First Author: Rongbo Lin

Question and Answer

Abstract 7: Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502).
First Author: Ken Kato, MD, PhD

Question and Answer

Abstract 8: Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.
First Author: Yoon-Koo Kang, MD, PhD

Question and Answer

1:00 PM-1:45 PM Breakout Session: Palliation of Esophago-Gastric Malignancies

Robert Shen, MD—Chair
Mayo Clinic

Bridget N. Fahy, MD
University of New Mexico
Managing Obstruction

Jennifer Yon-Li Wo, MD
Massachusetts General Hospital
Managing Bleeding

Panel Question and Answer
1:45 PM-2:15 PM Break
2:15 PM-3:45 PM

Oral Abstract Session A: Cancers of the Esophagus and Stomach

Robert Shen, MD—Chair
Mayo Clinic
Daniela Molena, MD—Chair
Memorial Sloan Kettering Cancer Center

Abstract 62: First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).
First Author: Yelena Yuriy Janjigian, MD

Abstract 2: Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
First Author: Takashi Kojima, MD

Harry H. Yoon, MD
Mayo Clinic
Discussion

Abstract 3: Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS).
First Author: David H. Ilson, MD, PhD

Abstract 4: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).
First Author: Manish A. Shah, MD, FASCO

Martine Extermann, MD, PhD
Senior Adult Oncology Program, H. Lee Moffitt Cancer Center and Research Institute
Discussion

Panel Question and Answer

3:45 PM-4:15 PM Break
4:15 PM-5:30 PM General Session 3: Personalized Therapy for Advanced Esophago-Gastric Malignancies

Rachna T. Shroff, MD—Chair
The University of Arizona Cancer Center

Manish A. Shah, MD, FASCO—Chair
Weill Cornell Medicine/ New York Presbyterian Hospital

Jaafar Bennouna, MD, PhD
University Hospital of Nantes
Integration of Immunotherapy

Anna Dorothea Wagner, MD
Lausanne University Hospital
Role of Targeted Therapy in Treatment

Karyn A. Goodman, MD, MS
University of Colorado School of Medicine
Incorporating Molecular and Imaging Biomarkers into Clinical Practice

Panel Question and Answer
5:30 PM-6:30 PM Poster Session A: Cancers of the Esophagus and Stomach
With Complimentary Wine and Cheese Reception
5:30 PM-6:30 PM Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach
5:45 PM- 6:30 PM

Poster Walks: Cancers of the Esophagus and Stomach

Daniela Molena, MD—Poster Walk Leader
Memorial Sloan Kettering Cancer Center

Abstract 28: Disparities associated with the receipt of palliative care in patients with metastatic gastric cancer.
First Author: Subhadeep Paul, BA

Abstract 81: A comparison of elderly versus nonelderly patients in the CRITICS gastric cancer trial.
First Author: Astrid E Slagter, MSc

Abstract 90: Multicenter prospective observational study of QoL after palliative surgery for patients with bowel obstruction caused by peritoneal dissemination of gastric cancer.
First Author: Yuichi Ito, MD, PhD

Abstract 94: Long-term effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients. 
First Author: Kazuhiro Nishikawa

Abstract 136: Gastric cancer liver metastasis: Optimal management for oligo-metastatic disease.
First Author: Hiromichi Ito, MD, FACS

Marcia Cruz-Correa, MD, PhD—Poster Walk Leader
The University of Puerto Rico and MD Anderson Cancer Center

Abstract 43: DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.
First Author: Raghav Sundar, MBBS

Abstract 44: MSI-low is an intermediate type between MSI-high and MSS in esophagogastric junction adenocarcinoma.
First Author: Yu Imamura, FACS, MD, PhD

Abstract 45: Genomic profile of gastric cancer in the United States versus East Asia.
First Author: Gregory A. Gilmore, DO

Abstract 66: MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).
First Author: Filippo Pietrantonio, MD

Abstract 111: Endoscopic submucosal dissection versus surgery for undifferentiated-type early gastric cancer: A meta-analysis.
First Author: Byung-Wook Kim, MD, PhD